Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic.
Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript February 23, 2024 Galapagos NV beats earnings expectations. Reported EPS is $2.39, expectations were $-2.23. Galapagos NV isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing […]
Galapagos NV (GLPG), a bio-pharmaceutical company, Tuesday said it entered into a deal to sell its Jyseleca business to Italian pharma company Alfasigma. As per the terms of the agreement, Michele Manto the Chief Commercial Officer of the company has resigned and will be joining Alfasigma in the same capacity.
Several analysts have recently updated their ratings and price targets for Galapagos (NASDAQ: GLPG): 5/18/2023 – Galapagos is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 5/9/2023 – Galapagos had its price target lowered by analysts at Morgan Stanley from $44.00 to $42.00. 5/8/2023 – Galapagos was upgraded by […]
Mechelen, Belgium; 5 May 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors.